EYPT
Income statement / Annual
Last year (2023), EyePoint Pharmaceuticals, Inc.'s total revenue was $46.02 M,
an increase of 11.14% from the previous year.
In 2023, EyePoint Pharmaceuticals, Inc.'s net income was -$70.80 M.
See EyePoint Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$46.02 M
|
$41.40 M
|
$36.94 M
|
$34.44 M
|
$20.37 M
|
$2.96 M
|
$7.54 M
|
$1.62 M
|
$26.57 M
|
$3.47 M
|
| Cost of Revenue |
$4.63 M |
$8.33 M |
$8.18 M |
$5.82 M |
$2.69 M |
$18.50 M |
$0.00 |
$815,000.00 |
$14.38 M |
$78,000.00 |
| Gross Profit |
$41.39 M |
$33.08 M |
$28.76 M |
$28.61 M |
$17.68 M |
-$15.54 M |
$7.54 M |
$805,000.00 |
$12.18 M |
$3.40 M |
| Gross Profit Ratio |
0.9 |
0.8 |
0.78 |
0.83 |
0.87 |
-5.25 |
1 |
0.5 |
0.46 |
0.98 |
| Research and Development
Expenses |
$64.66 M
|
$49.64 M
|
$28.50 M
|
$17.42 M
|
$15.37 M
|
$16.18 M
|
$14.88 M
|
$14.38 M
|
$12.09 M
|
$9.57 M
|
| General & Administrative
Expenses |
$40.10 M
|
$34.82 M
|
$25.58 M
|
$20.73 M
|
$17.94 M
|
$11.55 M
|
$11.24 M
|
$9.01 M
|
$8.06 M
|
$7.47 M
|
| Selling & Marketing
Expenses |
$11.69 M
|
$25.51 M
|
$27.50 M
|
$25.29 M
|
$29.77 M
|
$1.51 M
|
$1.51 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$51.79 M
|
$60.32 M
|
$53.08 M
|
$46.02 M
|
$47.71 M
|
$13.06 M
|
$11.24 M
|
$9.01 M
|
$8.06 M
|
$7.47 M
|
| Other Expenses |
$0.00 |
$2.05 M |
$2.46 M |
$2.46 M |
$2.46 M |
$14.84 M |
$8.31 M |
$13.98 M |
$3,000.00 |
$7.26 M |
| Operating Expenses |
$115.05 M |
$112.02 M |
$84.04 M |
$65.90 M |
$65.54 M |
$29.24 M |
$26.12 M |
$23.39 M |
$20.14 M |
$17.04 M |
| Cost And Expenses |
$121.09 M |
$120.34 M |
$92.22 M |
$71.73 M |
$68.23 M |
$29.24 M |
$26.12 M |
$23.39 M |
$20.14 M |
$17.04 M |
| Interest Income |
$6.95 M |
$2.13 M |
$292,000.00 |
$58,000.00 |
$1.05 M |
$101,000.00 |
$91,000.00 |
$72,000.00 |
$19,000.00 |
$6,000.00 |
| Interest Expense |
$1.25 M |
$3.19 M |
$5.50 M |
$7.26 M |
$6.18 M |
$720,000.00 |
$720,000.00 |
$0.00 |
$0.00 |
$1,000.00 |
| Depreciation &
Amortization |
$464,000.00
|
$2.45 M
|
$2.77 M
|
$2.65 M
|
$2.60 M
|
$2.65 M
|
$815,000.00
|
$815,000.00
|
$882,000.00
|
$917,000.00
|
| EBITDA |
-$69.00 M
|
-$96.62 M
|
-$50.15 M
|
-$35.49 M
|
-$48.01 M
|
-$36.99 M
|
-$18.58 M
|
-$17.67 M
|
-$20.87 M
|
$7.30 M
|
| EBITDA Ratio |
-1.5 |
-1.81 |
-1.42 |
-1.01 |
-2.18 |
-8.84 |
-2.46 |
-13.44 |
0.24 |
-3.64 |
| Operating Income Ratio
|
-1.63
|
-1.91
|
-1.5
|
-1.08
|
-2.35
|
-8.87
|
-2.46
|
-13.44
|
0.24
|
-3.88
|
| Total Other
Income/Expenses Net |
$4.36 M
|
-$2.62 M
|
-$3.14 M
|
-$8.10 M
|
-$8.93 M
|
-$63.17 M
|
-$26.90 M
|
$91,000.00
|
$72,000.00
|
$22,000.00
|
| Income Before Tax |
-$70.71 M |
-$102.25 M |
-$58.42 M |
-$45.39 M |
-$56.79 M |
-$53.17 M |
-$18.49 M |
-$21.70 M |
$6.44 M |
-$13.49 M |
| Income Before Tax Ratio
|
-1.54
|
-2.47
|
-1.58
|
-1.32
|
-2.79
|
-17.96
|
-2.45
|
-13.4
|
0.24
|
-3.88
|
| Income Tax Expense |
$83,000.00 |
$22.26 M |
$5.50 M |
$7.26 M |
$6.18 M |
-$25.56 M |
-$815,000.00 |
-$155,000.00 |
$96,000.00 |
-$130,000.00 |
| Net Income |
-$70.80 M |
-$124.51 M |
-$63.92 M |
-$52.65 M |
-$62.97 M |
-$53.17 M |
-$18.49 M |
-$21.55 M |
$6.35 M |
-$13.36 M |
| Net Income Ratio |
-1.54 |
-3.01 |
-1.73 |
-1.53 |
-3.09 |
-17.96 |
-2.45 |
-13.3 |
0.24 |
-3.85 |
| EPS |
-1.82 |
-3.34 |
-2.22 |
-4.1 |
-6.04 |
-11.5 |
-5.23 |
-6.81 |
2.16 |
-4.87 |
| EPS Diluted |
-1.82 |
-3.34 |
-2.22 |
-4.1 |
-6.04 |
-11.5 |
-5.23 |
-6.81 |
2.08 |
-4.87 |
| Weighted Average Shares
Out |
$38.90 M
|
$37.32 M
|
$28.76 M
|
$12.84 M
|
$10.43 M
|
$4.62 M
|
$3.53 M
|
$3.16 M
|
$2.94 M
|
$2.74 M
|
| Weighted Average Shares
Out Diluted |
$38.90 M
|
$37.32 M
|
$28.76 M
|
$12.84 M
|
$10.43 M
|
$4.62 M
|
$3.53 M
|
$3.16 M
|
$3.06 M
|
$2.74 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
